IR@PKUHSC  > 北京大学临床肿瘤学院  > 胸部肿瘤内科
学科主题临床医学
Anti-HDGF Targets Cancer and Cancer Stromal Stem Cells Resistant to Chemotherapy
Zhao, Jun1,3; Ma, Mark Z.1; Ren, Hening1,2; Liu, Zhenqiu2; Edelman, Martin J.2; Pan, Hong1,4; Mao, Li1,2
刊名CLINICAL CANCER RESEARCH
2013-07-01
DOI10.1158/1078-0432.CCR-12-3478
19期:13页:3567-3576
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]GROWTH-FACTOR ; LUNG-CANCER ; TUMOR MICROENVIRONMENT ; BREAST CARCINOMAS ; ANGIOGENESIS ; FIBROBLASTS ; BEVACIZUMAB ; INHIBITORS ; EXPRESSION ; PACLITAXEL
英文摘要

Purpose: Approximately one third of the patients with advanced non-small cell lung carcinoma(NSCLC) will initially respond to platinum-based chemotherapy, but virtually all tumors will progress (acquired resistance). The remainder will progress during initial treatment (primary resistance). In this study, we test whether the treatment can be improved by inhibiting hepatoma-derived growth factor (HDGF).

Experimental Design: Thirteen primary NSCLC heterotransplant models were used to test four treatment regimens, including platinum-based chemotherapy with and without bevacizumab (VEGF-neutralizing antibody) or HDGF-H3 (HDGF-neutralizing antibody) and chemotherapy with bevacizumab and HDGF-H3. Expression of stem cell-related genes was measured using quantitative reverse transcription PCR (qRT-PCR) and immunohistochemistry.

Results: Among 13 primary NSCLC heterotransplant models, three (23%) responded to chemotherapy but all relapsed within 20 days. The residual tumors after response to the chemotherapy exhibited an increased expression in 51 (61%) of 84 genes related with stem cell proliferation and maintenance, particularly those in Notch and Wnt pathways, suggesting enrichment for stem cell populations in the residual tumors. Interestingly, tumors from two of three models treated with HDGF-H3, bevacizumab, and chemotherapy combination did not relapse during 6 months of posttreatment observation. Importantly, this treatment combination substantially downregulated expression levels in 57 (68%) of 84 stem cell-related genes, including 34 (67%) of 51 genes upregulated after the chemotherapy.

Conclusion: These data support the hypothesis that cancer stem cells (CSC) are a mechanism for chemotherapy resistance and suggest HDGF may be a target for repressing CSCs to prevent relapse of NSCLC sensitive to chemotherapy. (C)2013 AACR.

语种英语
WOS记录号WOS:000321095900024
项目编号R01 CA126818 ; P30 CA134274
资助机构National Cancer Institute
引用统计
被引频次:23[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60631
专题北京大学临床肿瘤学院_胸部肿瘤内科
作者单位1.Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA
2.Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA
3.Peking Univ, Canc Hosp & Inst, Dept Thorac Med Oncol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100871, Peoples R China
4.Guangxi Univ, Affiliated Tumor Hosp, Dept Thorac Surg, Nanning 530004, Guangxi, Peoples R China
推荐引用方式
GB/T 7714
Zhao, Jun,Ma, Mark Z.,Ren, Hening,et al. Anti-HDGF Targets Cancer and Cancer Stromal Stem Cells Resistant to Chemotherapy[J]. CLINICAL CANCER RESEARCH,2013,19(13):3567-3576.
APA Zhao, Jun.,Ma, Mark Z..,Ren, Hening.,Liu, Zhenqiu.,Edelman, Martin J..,...&Mao, Li.(2013).Anti-HDGF Targets Cancer and Cancer Stromal Stem Cells Resistant to Chemotherapy.CLINICAL CANCER RESEARCH,19(13),3567-3576.
MLA Zhao, Jun,et al."Anti-HDGF Targets Cancer and Cancer Stromal Stem Cells Resistant to Chemotherapy".CLINICAL CANCER RESEARCH 19.13(2013):3567-3576.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhao, Jun]的文章
[Ma, Mark Z.]的文章
[Ren, Hening]的文章
百度学术
百度学术中相似的文章
[Zhao, Jun]的文章
[Ma, Mark Z.]的文章
[Ren, Hening]的文章
必应学术
必应学术中相似的文章
[Zhao, Jun]的文章
[Ma, Mark Z.]的文章
[Ren, Hening]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。